Clinical Cancer Research

Contents

May 1, 2007
Vol 13, No 9

Cancer Therapy: Clinical

Cancer Therapy: Preclinical

About the Cover

Treatment of established Colon 26 tumors with targeted (TNT-3/CD137L) or untargeted (Fc-CD137L) fusion proteins or the agonist antibody 2A directed against murine CD137 produces $CD8^+$ T-cell–dependent regression and complete remission in mice. Morphologic and immunohistochemical studies showed that both CD137L fusion proteins induced massive central necrosis and infiltration of granzyme B-positive cells in necrotic areas and viable peripheral regions of tumors. From these studies, it was determined that both targeted and untargeted CD137L fusion proteins demonstrated effective antitumor activity, providing convincing evidence that CD137L costimulation is a viable strategy for successful tumor immunotherapy. For further details, please see Zhang *et al.* on page 2758 in this issue.



Clinical Cancer Research

13 (9)

Clin Cancer Res 2007;13:2533-2821.